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ABSTRACT 
Leukemia is a cancer of marrow and blood, which is a clonal myeloproliferative disease, characterized by the presence of oncogenic Philadelphia 
chromosome, formed by a reciprocal translocation between chromosomes 9 and 22, resulting in the novel chimeric oncoprotein BCR/ABL. Chronic 
leukemia typically progresses slowly and permits the growth of greater numbers of more developed cells. If the cell change takes place in a type of 
marrow cell that normally goes on to form red blood cells, some kinds of white blood cells and platelets, the leukemia is called “myeloid. Therapy for 
chronic myeloid leukemia depends on the stage of CML patient. After diagnosis and confirmation of CML positive patient, treatment available for 
patients includes imatinib that is an early diagnosed treatment for CML but after some duration of time, it may lead to resistance to imatinib 
treatment. Dasatinib, nilotinib, bosutinib & ponatinib can be used for the treatment of CML as secondary treatments. Ponatinib is also found 
effective against T315i mutation patients. Omacetaxine mepesuccinate can be given with a mechanism of action independent of tyrosine kinase 
inhibition. Clinical trial for development of advanced therapy, which includes combination therapy and newer developed a treatment against CML 
are going on. It is required to develop better drug therapy, which will not cause genetical mutation and drug resistant. It is also required to find out 
thecause of resistance and what are the possible ways by which better therapy for CML is possible. 
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INTRODUCTION 
Leukemia is a cancer of the marrow and blood. The four major 
types of leukemia are acute myeloid leukemia, chronic myeloid 
leukemia, acute lymphoblastic leukemia and chronic lymphocytic 
leukemia. 
Acute leukemia is rapidly progressing disease that affects mostly 
cells that are partly or completely undeveloped. These immature 
cells cannot perform their normal functions. Chronic leukemia 
typically progresses slowly and permits the growth of greater 
numbers of more developed cells. In general, these more mature 
cells can carry out some of their normal functions. 
Chronic myeloid leukemia (CML) is called by several other names, 
including “chronic myelogenous leukemia,” “chronic granulocytic 
leukemia” and “chronic myelocytic leukemia” [1]. 
Extracellular vesicle (EV) is a way of intercellular communication. It 
communicates besides soluble factor and tunneling nanotubule. EVs 
transfer signals within or at their limiting membrane. It is providing 
a mechanism by which cells can exchange more complex 
information than previously thought [2–5]. It has been proven that 
in addition to proteins, mRNAs and microRNAs, there are DNA 
fragments within EVs [6–10]. By endocytosis or by fusion, the 
existence of DNA in EVs that could be transferred from one cell to 
another. The transferred EV DNAs have pathophysiological 
significance, not only to increase the DNA-coding mRNA and protein 
levels, but also influence the function of the recipient cells [6].  
Tumor-derived EVs are fully equipped to facilitate the escape of 
tumor cells from immune surveillance. While escaping tumor EVs 
also are involved in the establishment of an optimal environment for 
newly formed and metastatic tumor cells. It is interesting to find that 
the tumor-derived EVs could prod normal cells towards a tumor 
phenotype [11].  
CML is a clonal myeloproliferative disorder of a pluripotent stem cell 
first described by John Hughes Bennett in 1845 at The Royal 
Infirmary of Edinburgh [12]. 
As a special tumor, CML is a clonal myeloproliferative disease which 
is characterized by the oncogenic Philadelphia chromosome formed 
by a reciprocal translocation between chromosomes 9 and 22 that 
result in the novel chimeric protein BCR/ABL (breakpoint cluster 
region, BCR; Abelson murine leukemia viral oncogene, ABL), that 
dictates the pathophysiology of CML [2,14-16,17]. 
CML is an acquired stem cell disorder which is characterized by 
expression of the BCR-ABL oncoprotein. Animal models, as well as 
theoretical considerations on the age-specific incidence of CML in 
human populations, suggest that aberrant BCR-ABL expression alone 
may be enough to explain the chronic phase of the disease [18-24].  
Approximately 50 % of CML patients are 66 y and older. In the 
earlier studies age appeared a poor prognostic factor for survival 
and was included as such in all staging models. It is not clear 
whether this age effect was due to poorer disease biology, or to 
other age-related factors, including competitive causes of death, 
increased risk of treatment-related complications, or contra-
indications to the curative bone marrow transplant [25-28]. 
A systematic literature search was conducted on the electronic 
databases PubMed Central®, National Cancer Institute, American 
Society of Hematology (ASH), American Cancer Society®, National 
Comprehensive Cancer Network (NCCN) Guidelines®
In 1845, it was reported a “Case of hypertrophy of the spleen and 
liver in which death took place from suppuration of the blood”. Only 
a few weeks later, it was published a very similar case. Although one 
cannot know for sure, these two patients probably represent the 
first descriptions of the disease that later became known as CML. 
While it was thought that the patient had an infection. It was also 
suspected a neoplastic disorder that was soon called white blood 
disease or leukemia. In 1872, it was observed by one scientist that 
. The literature 
search covered the time period of 1960 to 2016. The search terms 
were keywords from MeSH with efficacy, resistance, and related 
concepts combined with the drug terms including synonyms within 
the approved indications. 
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leukemia cells originated in the bone marrow. The next decades saw 
the differentiation into myeloid versus lymphoid and acute versus 
chronic leukemia. 
A real quantum leap, however, was the discovery by Philadelphia 
cytogeneticists Peter Nowel and David Hungerford of an abnormally 
small G-group chromosome that we now call the Ph chromosome.  
In the 1980s, the translocation partners were identified as BCR and 
ABL, followed by the discovery that unregulated tyrosine kinase 
activity is critical to BCR-ABL’s ability to transform cells. A faithful 
murine disease model established in 1990. 
Therapy for CML was developed slowly. In 1865, it was described 
that use of arsenic is nothing too novel because the use of arsenic for 
cancer therapy had been described in the Indian Ramayana more 
than 2000 y earlier. Splenic irradiation was introduced in the 1920s 
for symptomatic relief. Effective control of blood counts became 
feasible with busulfan (1959), followed 10 y later when the better-
tolerated hydroxyurea became available, probably the first 
intervention with a (modest) prolongation of survival. In the mid-
1970s, a breakthrough was achieved when the Seattle group 
reported the disappearance of the Ph chromosome in CML patients 
who underwent allotransplant, the first cure of CML. Soon later, 
interferon-α was found to induce durable complete cytogenetic 
responses and long-term survival, although in only a small fraction 
of patients. In 1992, Alexander Levitzki proposed the use of ABL 
inhibitors to treat leukemia driven by ABL oncogenes. At about the 
same time, scientists at Ciba-Geigy had synthesized a potent 
inhibitor of ABL that was termed GCP57148B and is now known as 
imatinib.  
In 2008, the majority of patients diagnosed with chronic phase 
myeloid leukemia can expect to have durable responses with good 
quality of life. From 20% to 30% patients who fail for imatinib 
treatment, second-line treatments are an effective salvage strategy. 
However, once the disease has progressed beyond the chronic 
phase, allotransplant is still the recommended treatment for all 
eligible patients. Unfortunately, residual leukemia may persist even 
in the best responders and that therapies directed at the BCR-ABL 
tyrosine kinase are not curative since they fail to eradicate the CML 
stem cells. Thus, the CML saga continues and much work remains to 
be done [29]. 
CML is a rare hematologic cancer that originates in the bone 
marrow. It represents about 20% of all leukemia, and an estimated 
5,000 new patients were diagnosed with the disease in the United 
States in 2010. The disease is slightly more common in men than it is 
in women and it primarily affects older individuals. Although the 
median age at diagnosis is 65 y, it can occur across the lifespan: in 
the years 2004 to 2008, 20% of patients were diagnosed at age 44 y 
or younger, 30% between ages 45 to 64 and 50% at age 65 or older 
[30, 31]. 
Significant advances in the treatment of CML have increased the 
survival rate significantly. In 1975, the 5-year survival rate for a 
newly diagnosed patient was 19%; in 2002, it was 53%. With 
tyrosine kinase inhibitor (TKI) therapy, the most recent overall 
survival (OS) rate with 8 y of treatment was 85% [30, 32]. With 
prolonged survival, CML can be managed in a manner similar to that 
used for a serious illness [30, 33] with an emphasis on ongoing 
patient education, support and symptom management [30]. 
Mechanism of chronic myeloid leukemia 
Approximately 90% of patients with CML have an acquired genetic 
abnormality, the Ph chromosome [34]. The Ph is a shortened 
chromosome 22 resulting from a reciprocal translocation between 
the long arms of chromosomes 9 and 22t (9;22q34;q11) [35, 36]. In 
this translocation, the c-ABL proto-oncogene is transposed from its 
normal position on chromosome 9 to a 5.8 kb major breakpoint 
cluster region M-BCR on chromosome 22, forming a BCR-ABL fusion 
gene [36, 37]. The new gene encodes p210BCR/ABL, an oncoprotein 
that has increased tyrosine kinase (TK) activity [38, 39] and 
increased binding to the actin cytoskeleton [40] compared with the 
p145 Abelson protein, both of which contribute to transformation. 
The presence of p210BCR/ABL causes growth factor independence 
and leukemic cell growth in hematopoietic cell lines [41-43]. 
Transplantation of BCR-ABL-transduced hematopoietic stem cells or 
transgenic expression of p210BCR/ABL induces leukemia, 
lymphomas and CML-like syndromes [44-52] proving the direct 
causal relationship to CML. 
The p145ABL protein, the product of the Abelson gene, is a TK 
whose function is not totally known. There is evidence that p145ABL 
is important for cell growth [53-55], induction of apoptosis [56-58] 
and is involved in DNA repair [59-61]. Although p145ABL is found 
mainly in the cell nucleus, there is mounting evidence that it plays a 
role in cell signalling from integrin’s [62] as well as other cell surface 
receptors such as the B cell receptor and CD19 [34, 63]. 
Risk factors for chronic myeloid leukemia 
• High dose radiation, such as an atomic bomb blast or nuclear 
reactor accident 
• Age (the risk of getting CML goes up with age) 
• Gender (this disease is slightly more common in males than 
females, but it's not known why) 
Sign and symptoms of chronic myeloid leukemia 
General symptoms of CML can include weakness, feeling very tired 
most of the time (fatigue), night sweats (that drench the sheets), 
weight loss (without trying), fever, bone pain, enlarged spleen (felt 
as a mass under the left side of the ribs), pain or sense of "fullness" 
in the belly, feeling full after eating even a small amount of food, 
bone or joint pain. 
Many of the symptoms of CML happen because the leukemia cells 
crowd out the cells that make blood in the bone marrow. As a result, 
the person does not have enough blood cells and platelets that are 
working the way they should. 
• Anemia is a result of a shortage of red blood cells. It can make a 
person feel short of breath, tired, cold, lightheaded and weak. 
• Not having enough normal white blood cells (leukopenia) 
increases the risk of infections. 
• Not having enough blood platelets can lead to easy bruising, 
bleeding, frequent or severe nosebleeds, and bleeding gums [64]. 
Diagnosis of chronic myeloid leukemia 
Routine blood tests 
Blood cell counts and blood cell exam 
The complete blood count (CBC) is a test which measures the levels 
of different blood cells, such as red blood cells (RBC), white blood 
cells (WBC), and platelets. This is the first test require if it has been 
suspected leukemia or other blood problem. In CML patients have 
increased the level of WBC and decreased the level of RBC or blood 
platelets. These findings may suggest leukemia, but it usually needs 
to be confirmed with another blood test or a test of the bone 
marrow. 
Blood chemistry tests  
These tests are not required to confirm if a person has leukemia or 
not. But for patients already known to have CML, these tests require 
deciding that patient doest not has liver or kidney problems caused 
by the spread of leukemia cells or by the side effects of certain drugs 
used for treatment. These tests decide that the patients require any 
treatment to correct low or high blood levels of certain minerals. 
Examine under a microscope 
Blood and bone marrow samples need to observe under a 
microscope by a pathologist. The pathologist will observe the size 
and shape of the cells as well as other features to divide the cells into 
specific types. This process is to see whether or not the cells look 
mature. The most immature cells are called blasts. The blasts do not 
work the way they should, and they can keep on forming new cells, 
crowding out normal, mature cells. 
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Genetic tests 
Chromosomes are long chains of DNA found in every cell. 
Chromosome mutation which leads to CML is called the Philadelphia 
chromosome. Ph chromosome found in the leukemia cells of almost 
all patients with CML, which can be by cytogenetic, FISH and PCR 
methods in samples of blood and/or bone marrow. 
Imaging tests 
Imaging tests are used to take images of the inside of the body. They 
are not used to find CML, but they may be done to help fig. out if it 
involves certain organs (like the spleen). 
CT (Computed tomography) scans 
CT scan is a special kind of x-ray in which a beam of light moves 
around the body, taking images from many angles. CT scans are not 
required to find CML, but may be done if leukemia is growing in 
other parts of a boy like in spleen. 
MRI (Magnetic resonance imaging) 
MRI scans are very helpful for imaging of the brain and spinal cord. 
Powerful magnets and radio waves have been used in this test to 
make images of the inside of the body. It takes longer time than CT 
scans up to an hour.  
Ultrasound 
Ultrasound test uses sound waves to make images of internal 
organs. Ultrasound can look for enlarged organs in the belly 
(abdomen). This test is a very easy to perform on patients compared 
to other machinery tests. For most scans, you lie on a table and a 
technician moves a kind of wand (transducer) over the part of the 
body being looked at, which is first smeared with a gel. 
Chest x-ray 
A chest x-ray is only a plain x-ray of the chest. It is only used to find if 
someone has CMLwith lung problems. 
Staging of chronic myeloid leukemia 
Staging is the process of finding out how far cancer has spread. Most 
types of cancer are staged based on the size of the tumor and how 
far it has spread from where it started. This system does not work 
for leukemias because they do not often form a solid mass or tumor. 
Also, leukemia starts in the bone marrow and, in many people; it has 
already spread to other organs when it is found. 
Phases of chronic myeloid leukemia 
CML is divided into 3 phases that help predict the patient’s outlook. 
Doctors call these phases rather than stages. The phases are based on the 
number of immature white blood cells, called blasts, that are seen in the 
blood or bone marrow. From less to more serious, they are:  
• Chronic phase 
• Accelerated phase 
• Blast phase (also called acute phase or blast crisis) [64] 
Chronic phase 
People with chronic phase CML may have no symptoms during this 
phase, or CML symptoms may be present prior to treatment due to 
changes in blood cell counts or spleen enlargement. If present, 
chronic phase symptoms resolve promptly when people are treated. 
Effective therapy initially lowers the total white cell count to near-
normal levels. The improved white cell count is accompanied by a 
reduction in spleen enlargement, improvement in the haemoglobin 
concentration and return to general well-being. Bleeding and 
infectious complications are uncommon in the chronic phase. Once 
treated, people with chronic phase CML are typically able to 
participate fully in their usual activities.  
Anemia may develop or progress and cause fatigue, the white cell 
count may either fall to very low levels or rise because of the 
accumulation of blast cells, and platelet counts generally decrease. 
The blast count often increases in the blood and bone marrow in the 
accelerated phase (and is further elevated in blast crisis). The spleen 
may become enlarged; the patient may lose his or her sense of well-
being (in this phase, individuals more commonly feel ill) and other 
complications may follow. 
Accelerated phase  
An optimal response is defined as no indication that a change of 
therapy may improve a patient’s survival. A suboptimal response is 
where the patient may still have a substantial long-term benefit from 
continuing the ongoing specific treatment, but the chances of an 
optimal outcome are considerably reduced, and thus, suboptimal 
responders may be eligible for alternative approaches. A failed 
Blast crisis 
In this phase, the number of blast cells increases in both bone 
marrow and blood; the red cell, platelet and neutrophil counts can 
be very low, and patients may experience episodes of infection and 
bleeding as a result. Other symptoms commonly encountered 
include fatigue, shortness of breath, abdominal pain, bone pain 
and/or spleen enlargement. Unfortunately, blast crisis is similar to 
acute leukemia in its effects on the patient. In about 25 percent of 
people, the transformation in the blast crisis takes on the 
appearance of acute lymphoblastic leukemia, while in the majority it 
takes on the appearance of acute myeloid leukemia [1]. 
Clinical evidence indicates that all CML patients undergoing imatinib 
treatment should be monitored closely in order to assess their 
response to therapy and to detect early relapse. There are three 
different types of responses in CML: (1) Haematological Response 
(HR), (2) Cytogenetic Response (CR) and (3) Molecular Responses 
(MR). A complete hematologic response (CHR) is defined as the 
normalization of blood counts and spleen size. Blood counts can be 
assessed using biweekly testing until a CHR is attained and then 
testing can be performed every 3 mo. Cytogenetic monitoring is the 
most widely used technique to monitor response to patients with 
CML [65]. Typically, it is quantitated by determining the decrease in 
the number of Ph+metaphase cells using both bone marrow 
aspiration and cytogenetic evaluation techniques.  
A major cytogenetic response (MCR) is said to be achieved when 
Ph+metaphase is present in 0–35% of cells. In contrast, the absence 
of Ph+metaphase cells leads to complete CR (CCR). Fluorescent in 
situ hybridization (FISH), which analyzes a higher number of cells 
(up to 200), can be used instead of conventional cytogenetic 
assessment for quantifying cells that are Ph+. However, a significant 
background level of false-positive results limits the use of FISH and 
prevents full correlation with the conventional assessment.  
The recent European Leukemia Net (ELN) recommendations[66] 
suggests cytogenetic testing first at 3 and 6 mo, then every 6 mo 
until a CCR is achieved and confirmed and subsequently every 12 mo 
if regular molecular monitoring cannot be assured. An MR is 
determined by a decrease in the amount of BCR-ABL chimeric 
mRNA. A complete molecular response (CMR) is achieved when 
there is no detectable BCR-ABL chimeric mRNA as assessed by 
reverse transcriptase-polymerase chain reaction (RT-PCR). 
The methodology of RT-PCR is probably the most sensitive assay to 
detect BCR-ABL chimeric mRNA; in fact, it can detect even one CML 
cell with a background of more than 100,000 normal cells. 
Quantitative RT-PCR (Q-PCR) measures the actual percentage of BCR-
ABL mRNA transcripts and shows a significant correlation between 
the results obtained from peripheral blood and the bone marrow. 
The cytogenetic and molecular monitoring of the response to TKIs 
treatment provides important prognostic information. A 5-year 
follow-up in the IRIS study showed that no patients progressed to 
the accelerated blast phase after 12 mo if a CCR and an MMR were 
obtained [69]. The estimated progression-free survival (PFS) at 24 
mo was 100% for patients who received CCR and MMR at 12 mo 
[69]. Monitoring the response to second-generation TKIs requires 
the same tests, but earlier and more frequent testing may be 
appropriate because responses are more rapid. On the basis of the 
magnitude of HR, CR and MR, and on the time when these responses 
are achieved, the overall response to imatinib can be defined as 
optimal, suboptimal or failed (table 2). 
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response indicated that a favorable outcome is unlikely and that the 
patient should receive a different treatment whenever available and 
applicable. The definition of the response to the second-generation 
TKIs dasatinib and nilotinib as second-line therapy of patients with 
imatinib-resistant CML-CP was also provided by the new ELN 
recommendation (table 3) [66]. 
 
Table 1: Criteria for haematological, cytological and molecular response [66] 




Complete normalization of peripheral blood count: white blood cell count<10*109 L-1, 
platelet count<450*109 L-1
Check every 2 w until CHR 
achieved, then monitor every 3 
mo 
; no immature cells; no splenomegaly 
Partial Same as complete haematological except for; persistent of immature cells; platelet 
count<50% of pretreatment count, but>450*109L-1
 
; splenomegaly<50% of pre-treatment 




O Ph+metaphases Check every 6 mo until CCR 
achieved then every 12-18 mo 
Major(MCR) 0-35% Ph+metaphases (complete+partial)  
Partial 1-34% Ph+metaphases  




BCR-ABL mRNA undetectable by RT-PCR;  
>=3 log reduction of BCR-ABL mRNA 
Check every 3 mo 
Major (MMR)  
Ph+: Ph-positive chromosome 
 




 Optimal  Suboptimal Failure 
3 mo CHR and at least minor CR 
(Ph+=<65%R) 
No CR (Ph+>95%) Less than CHR 
6 mo At least MCR (Ph+=<35%) Less than MCR (Ph+>35%) No CR (Ph+>95%) 
12 mo CCR Less than CCR Less than MCR (Ph+>35%) 
18 mo MMR Less than MMR Less than CCR 
Any Stable or improving MMR Lose of MMR ABL kinase domain mutation 
predicted to confer low-level resistant 
Lose of CHR loss of CCr ABL kinase domain 
mutation predicted to confer high-level resistant 
CML: Chronic Myeloid Leukemia, HR: Haematological Response, CR: Cytogenetic Response, CHR: Complete Haematological Response, MCR: Major 
Cytogenetic Response, CCR: Complete Cytogenetic Response, MMR: Major Molecular Response 
 
Table 3: Definitions of the response to second-generation TKI (a second-line therapy) in Imatinib-resistant or intolerant chronic phase 
CML patients [66] 
Evaluation time Response 
Suboptimal Failure 
3 mo Minor CR (Ph+36-65%) No CR(Ph+95%); new mutations 
6 mo  PCR (Ph+1-35%) Minimal CR(Ph+66-95%); new mutations 
12 mo Less than MMR Less than PCR(Ph+35%); new mutations 
TKI: Tyrosine Kinase Inhibitors; Ph+: Philadelphia Chromosome Positive; CR: Cytogenetic Response; PCR: Partial Cytogenetic Response; MMR: 
Major Molecular Response 
 
However, the presence of a small number of point mutations and 
amplification of BCR-ABL kinase level lead to the emergence of 
resistance, resulting in relapse episodes in patients who were in a 
CCR on imatinib therapy [70]. Point mutations in BCR-ABL kinase 
domain are frequently involved in imatinib resistance and may be an 
important determinant in clinical decisions (discussed later). 
However, current evidence does not support mutation screening on 
a routine basis unless there is an indication of a loss of response. 
Several recent reports suggested that routine mutation screening 
could provide valuable information, such as predicting response to 
specific TKIs and identifying patients at high risk of disease 
progression [71, 72]. In addition, BCR-ABL Q-PCR monitoring results 
can be used to select patients with an increased risk of mutation, 
since some studies showed that elevations in BCR-ABL transcript 
levels might indicate a potential for BCR-ABL gene mutations and 
the emergence of imatinib resistance [73-75]. However, the optimal 
cut-off of increased BCR-ABL mRNA to predict mutation is still 
controversial. The National Comprehensive Cancer Network 
(NCCN) guidelines provisionally recommended mutation 
screening in cases with a 10-fold or greater increase of BCR-ABL 
mRNA is detected [65]. However, a study by Press et al. showed 
that a 10-fold threshold to trigger mutation screening was 
insensitive and not universally applicable, and a 2.6-fold increase 
in BCR-ABL mRNA was the optimal cut-off for predicting a 
concomitant mutation [76]. 
Comorbidities of the patient, the side effect profile, and the cost of 
the TKI of interest should be an important consideration in decision 
making. Whatever TKI is chosen as frontline, noncompliance or 
treatment failure should be recognized early as a prompt 
intervention increases the chance of achieving best possible 
response [77]. 
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Therapeutic monitoring 
The first generation of TKI 
Imatinib was the first FDA (Food and Drug Administration) 
approved TKI for the treatment of advanced stage Ph+CML patients. 
This was information from two successful phase II studies in CML-
AP and CML-BC patients [78, 79] using 600 mg/day of imatinib. 
Previous phase I and phase II clinical studies in CML patients 
resistant or intolerant to rIFN-α confirmed its clinical efficacy and 
safety [80, 81]. Imatinib is also approved by the FDA as a first-line 
treatment for patients with CML-CP based on data from a 
randomized phase III trial known as IRIS [82] that compared 
Imatinib 400 mg daily with IFN-α plus cytosine arabinoside (Ara-C) 
in 1106 previously untreated CML-CP patients. The crossover was 
allowed in patients that experienced treatment failure or intolerance. 
The most recent 6-year update data reported that 63% of all patients 
randomized to receive imatinib were still on study treatment and 
showed a CCR at the last assessment. The best cumulative CCR rate 
was 82%; the estimated event-free survival at 6 y was 83%. In 95% of 
patients, imatinib was well tolerated, as only 5% of patients 
discontinued treatment due to adverse effects. Moreover, no new 
adverse events were reported following long-term use of imatinib 
[83]. However, due to the relatively high rate of crossovers (~90%) 
from rIFN-α plus Ara-C group to imatinib group within a year of the 
study, perplexes the true determination of the survival benefit with 
Imatinib versus IFN-α plus Ara-C in the IRIS study. Until now, the 
maximum tolerated dose of imatinib had not been established, and an 
initial dose of 400 mg daily for adult CML-CP patients was 
recommended. Several prospective, non-randomized studies reported 
that responses to imatinib were more rapid and superior in the 
patients who were treated with doses of 600 or 800 mg daily [84, 85]. 
Although first-line imatinib treatment achieved an extremely high 
response rate and a low relapse rate in CML patients, some patients 
do experience imatinib resistance or intolerance. In 31% of patients 
who did not achieve a CCR during 12 mo of treatment and 13% still 
had not achieved CCR after 5 y of treatment. In addition, 3–7% of 
patients in that trial, experienced treatment failure during the first 3 
y and 5% of patients discontinued imatinib because of intolerable 
adverse effects [69]. Therefore, many patients require alternative 
treatment in the case of imatinib failure or intolerance. 
Imatinib has characterized a revolution in the treatment of CML 
drastic modification in overall survival. However, with 400 mg 
dosage of imatinib, one-third of the treated patients does not reach 
the criteria associated with an optimal outcome and could 
potentially benefit from a different treatment strategy. Several trials 
for modified imatinib-based treatments and second-generation 
tyrosine kinase as front-line therapy have been performed. In some 
studies, high-dose (800 mg per day) or dose-adapted imatinib or 
imatinib plus interferon was reported to be better cytogenetic and 
molecular responses compared with standard-dose imatinib, 
although no improvements in progression-free survival (PFS) or 
overall survival (OS) have been so far reported [86]. 
Efficacy data are comparable for first and second generation TKIs, and so 
physicians should consider the BCR-ABL1 mutation profile while 
prescribing drug therapy to patients who are resistance to first 
generation TKIs. Few BCR-ABL1 mutations seem to be less responsive to 
any of the three second-line TKIs, and therefore, it is recommended to 
choose the second-line TKI which has shown clinical activity against the 
specific mutation in these cases. For patients with all other mutations 
and for patients with no mutations, it is recommended to choose the 
second-generation TKI based on the patient's disease history. If dasatinib 
or nilotinib get fail, a third-generation TKI ponatinib is available for 
patients with T315I mutations. However, the optimal dose of ponatinib 
is still under investigation. Overall, it is recommended to select a drug 
that minimizes the likelihood of worsening the patient's past side effects 
or comorbid conditions [87]. 
The second-generation of TKIs 
Dasatinib 
As mentioned above, dasatinib inhibits a number of kinases, 
including BCR-ABL and Src and is more potent than imatinib against 
BCR-ABL TKs [88, 89]. Dasatinib has been clinically evaluated in 
phases I, II, and III trials in adult’s Ph+CML patients, who are 
intolerant or resistant to imatinib therapy. A phase I study [90] 
reported the effects of dasatinib (15–240 mg/day) once or twice 
daily in 4 w treatment cycles in the patients with various phases of 
CML or with Ph+ALL that could not tolerate or were unresponsive to 
imatinib treatment.  
The results indicated that a CHR was achieved in 37 out of 40 CML-
CP patients, an MHR in 31 of 44 CML-AP and MCR in 45% CML-BC or 
25% Ph+ALL patients. A response was maintained in 95% of 
patients with chronic phase disease and in 82% of patients with 
accelerated phase disease after median follow-up periods of more 
than 12 and 5 mo, respectively. In addition, the highest dose of 
dasatinib (240 mg) was well tolerated, with significant clinical 
responses occurring among all BCR-ABL genotypes, except for those 
with the T315I mutation. 
Several phase II studies, known as the SRC/ABL Tyrosine Kinase 
Inhibition Activity Research Trials (START) that examined the effect 
of dasatinib in Ph+CML patients resistant to imatinib or intolerant of 
its adverse effects. Dasatinib also induced aMR, and significantly 
decreased the BCR-ABL/ABL transcript ratios from 66% at baseline 
to 2.6% after 9 mo [91]. 
Grade 3/4 thrombocytopenia and neutropenia were reported in 
48% and 49% of the patients, respectively. Non-hematologic toxicity 
(any grade) consisted primarily of diarrhea (37%), headache (32%), 
fatigue (31%), dyspnea (30%) and pleural effusion (27%). Pleural 
effusions were classified as grade 3 in 6% of reported events, with 
no reports of grade 4 (table 5) [92]. 
The randomized phase II trial (Src-ABL Tyrosine kinase Inhibition 
Activity Research Trial (START)-R) [93] compared 400–600 mg/day 
of imatinib to a high dose (800 mg/day) of Imatinib in CML-CP 
patients resistant to imatinib. A total of 150 patients were 
randomized (2:1) to receive treatment with dasatinib 70 mg twice 
daily (n = 101) or imatinib 800 mg daily (n = 49). After a median 
follow-up of 15 mo, dasatinib produced a significantly greater CHR 
(93% vs. 82%, p = 0.034) and MCR (52% vs. 33%, p = 0.038) rate 
compared to 800 mg of imatinib. An MMR was also more frequent 
with dasatinib than imatinib treatment (16% vs. 4%; p = 0.038). The 
probability of treatment failure was lower [hazard ratio (HR) = 0.16] 
but the PFS was significantly greater (HR = 0.14) in dasatinib-
treated patients. Furthermore, the most recent 2-year follow-up 
results confirmed the significant PFS and OS benefit with dasatinib 
versus high-dose imatinib for these patients (table 4) [94]. 
The START-A trial evaluated the safety and efficacy of dasatinib in 
CML-AP patients with resistance or intolerance to imatinib [95]. An 
8-month follow-up of the first 107 patients enrolled in the study 
indicated an overall, major or complete HR was obtained in 81%, 
64% and 39% of patients, respectively. In addition, 33% and 24% of 
these patients attained a major or complete CR, respectively. In 69 
patients who achieved an MHR, only 7 relapsed and progressed to 
the disease, however, 76% of patients were estimated to be alive 
and were progression-free after 10 mo.  
The response rates in 60% of patients with baseline BCR-ABL 
mutations did not differ from the total population. Dasatinib was 
well tolerated, and no imatinib-intolerant patients discontinued 
dasatinib because of AEs. The follow-up data from all 174 patients 
have confirmed the safety and efficacy of dasatinib for CMP-AP 
patients with resistance or intolerance to imatinib. After a median 
follow-up of 14.1 mo, an MHR and CHR were attained in 64% and 
45% of patients respectively, and an MCR and CCR were achieved in 
39% and 32% of patients, respectively (table 4). These responses 
were achieved irrespective of the imatinib status (resistance or 
intolerance), prior stem-cell transplantation or the presence of a 
prior BCR-ABL mutation. The 12-month PFS and OS in these patients 
were 66% and 82%, respectively [96]. 
The efficacy of dasatinib for CML-BC patients with Imatinib 
resistance or intolerance was evaluated in the START-B (myeloid 
blast crisis, MBC-CML patients) and START-L (lymphoid blast crisis, 
LBC-CML patients) trials [97, 98]. 
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Table 4: Initial phase II data for second-line therapy with dasatinib or nilotinib after Imatinib failure in Philadelphia chromosome-
positive CML patients [94] 










Dasatinib Single arm trail in imatinib resistant or intolerant CML-CP patients 
(START-C) 
387 15.2 91 59 49 
Randomized 2-arm trail in Imatinib resistant CML-CP patients 
(START-R) 
101 24 93 53 44 
Single arm trail in imatinib resistant or intolerant CML-AP patients 
(START-A) 
174 14.1 45 39 32 
Single arm trail in imatinib resistant or intolerant MBC-CML 
patients (START-B) 
109 12 25 33 26 
Single arm trail in imatinib resistant or intolerant LBC-CML patients 
(START-L) 
48 12 29 52 46 
Nilotinib Single arm trail in imatinib resistant or intolerant CML-CP patients 321 19 94 59 41 
Single arm trail in imatinib resistant or intolerant CML-AP patients  137 11 31 32 20 
CML: Chronic Myeloid Leukemia, CP: Chronic Phase, AP: Accelerated Phase, MBC: Myeloid Blast Crisis, LBC: Lymphoid Blast Crisis, CHR: Complete 
Hematological Response, MCR: Major Cytogenic Response, CCR: Complete Cytogenic Response, START: Src-ABL Tyrosine kinase Inhibition Activity 
Research Trial 
 
In the LBC-CML patients, the 8-month and 12-month follow-up 
results indicated that the MHR rates were 31% and 35%, 
respectively, and the MCR rates were 50% and 52%, respectively. 
The median PFS and OS were 3.0 and 5.3 mo, respectively. The 
initially approved dose of dasatinib for CML patients resistant or 
intolerant to imatinib was 70 mg twice daily. However, a longer 
follow-up of the data from the phase I trial of dasatinib indicated 
that the once-a-day treatment group experienced significantly fewer 
adverse effects compared to those treated twice daily [90]. In 
addition, the median daily doses for patients with CML-CP during 
the START-C and START-R trials were 101 mg and 103 mg, 
respectively [91, 93]. In the CA180-035 trial, the efficacy and safety 
of 140 mg dasatinib once daily were compared to the 70 mg twice-
daily regimen in CML-AP patients with imatinib resistance or 
intolerance. After a median follow-up of 15 mo, 140 mg dasatinib 
daily doses demonstrated equivalent efficacy but improved safety 
compared to the 70 mg twice-daily regimen [101]. Therefore, based 
on data from this phase III studies, the FDA has approved dasatinib 
100 mg daily for CML-CP patients and 140 mg daily for CML-AP and 
CML-BC patients [65]. 
Currently, the efficacy of dasatinib is being evaluated as a first-line 
treatment in previously untreated CML-CP patients in an ongoing 
phase II trial by Borthakur and Kantarjian [102]. The results 
indicated a rapid CCR and a favorable toxicity profile with dasatinib 
treatment.  
Nilotinib 
The FDA approved nilotinib, another second-generation BCRABL 
tyrosine kinase inhibitor, in 2007 for the treatment of Imatinib 
resistance or intolerance in CML patients. In a phase I dose 
escalation study, nilotinib was found to be significantly more 
effective than imatinib-resistant CML patients, with a relatively 
favorable safety profile compared to imatinib [103]. Subsequently, a 
phase II trial was conducted [104] where 280 imatinib-resistant or 
intolerant patients were enrolled and treated with 400 mg b. i.d. of 
nilotinib. The MCR and CCR rates after a 6 mo follow-up were 48%, 
and 31%, respectively. Survival past 12 mo was estimated to be 95% 
in the nilotinib-treated patients. Nilotinib was effective in patients 
harboring BCR-ABL mutations associated with imatinib resistance 
(except T315I) and also in patients with a resistance mechanism 
independent of BCR-ABL mutations. The reported AEs were mostly 
mild to moderate, and there was minimal cross-intolerance to 
imatinib. A minimum 19-month follow-up result of all 321 patients 
enrolled in the study showed that nilotinib produced a rapid and 
sustained CHR and MCR rates. A CHR and MCR were observed in 
94% and 59% of patients, respectively, and 78% of patients 
maintained an MCR after 24 mo. The estimated OS rate was 88% at 
24 mo. The safety profile of dasatinib did not change with longer 
follow-up intervals [105]. Le Coutre et al. [106] conducted a phase II 
trial evaluating the efficacy and safety of nilotinib in CML-AP 
patients with resistance or intolerance to imatinib. Initially, 119 
patients were enrolled with median treatment duration of 202 d. 
The HR and MCR rates were 47% and 29%, respectively, and the 12 
mo OS rate was 79%. Non-hematologic AEs reported were mostly 
mild to moderate in severity. The most common grade 3 or higher 
hematologic AEs were thrombocytopenia (35%) and neutropenia 
(21%). Grade 3 or higher bilirubin and lipase elevations occurred in 
9% and 18% of patients, respectively, resulting in treatment 
discontinuation in 1 patient. Long-term follow-up results of the total 
137 patients confirmed that nilotinib induces a rapid and sustained 
response in CML-AP patients who do not respond to prior imatinib 
treatment, and there was a significantly favorable risk/benefit ratio. 
The HR, CHR, MCR and CCR rates were 56%, 31%, 32% and 20%, 
respectively, and the median time to HR was 1month. After 24 mo, 
54% and 70% of patients maintained HR and MCR, respectively, and 
the estimated OS at 24 mo were 67%. Only 9% of patients 
discontinued therapy due to drug-related AEs [106]. Thus, based on 
the results from the above studies, the food and drug administration 
(FDA), in 2007, approved nilotinib for the treatment of Ph+CML-CP 
or CML-AP patients with resistance or intolerance to imatinib. 
Nilotinib has also been shown to have efficacy in CML-BC patients. A 
phase II study reported the safety and efficacy data in 136 CML-BC 
patients treated with nilotinib. The results showed that the HR, MCR, 
CCR rates were 21%, 40% and 29%, respectively and the OS was 
42% at 12 mo [104]. However, more than half of the patients 
discontinued treatment due to disease progression and therefore, 
the FDA has not approved nilotinib for the treatment of CML-BC 
patients at this time. The efficacy of nilotinib was evaluated in 
another phase II trial (GIMEMA CML Working Party) as a first-line 
treatment in previously untreated CML-CP patients [108]. A total of 
73 patients were enrolled and followed up for 210 d. In the intent to 
treatment (ITT) analysis, the CHR rates at 3 and 6months were 
100% and 98%, respectively, and the CCR rates were 78% and 96%, 
respectively. The cytogenetic and molecular responses to nilotinib 
were significantly faster than that of imatinib. Only 1 patient with 
the T315I mutation progressed to the accelerated or blast phases at 
6 mo. All AEs (grade 3/4) were manageable by appropriate dose 
adjustments [109, 110]. 
Bosutinib 
Bosutinib is an orally administered Src/ABL inhibitor, estimated to 
be 45 to 50 times more potent than imatinib, with the minimal 
inhibitory activity of PDGFR and c-KIT [111]. This increased 
specificity is expected to produce less myelosuppression and fluid 
retention than other TKIs. The phase I study identified a treatment 
dose of 500 mg daily and showed evidence of clinical efficacy. Phase 
II studies in patients with CML-CP, who have failed imatinib and 
second-generation TKIs therapy are ongoing [112, 113]. Preliminary 
data for response to bosutinib among patients in chronic, 
accelerated, and blast phase (myeloid and lymphoid) after imatinib 
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failure are summarized in table 5. The most common AE with 
bosutinib were gastrointestinal (nausea, vomiting, diarrhea); these 
were usually grade 1-2, manageable and transient, diminishing in 
frequency and severity after the first 3-4 w of treatment. Bosutinib is 
being assessed in the front-line setting for treatment of patients who 
have CML-CP. 
 
Table 5: Response to second-generation TKIs (Dasatinib, Nilotinib, and Bosutinib) in patients who are Imatinib-resistant or intolerant to 
chronic phase, accelerated phase and blast phase [113] 
Response Percent response 




































15 14 12+ 12+ 24 9 3 3 7 6 3 





- 79 50 40 94 56 22 19 85 54 36 
CHR 91 45 27 29 76 31 11 13 81 54 36 
NEL - 19 7 6 - 12 1 0 - 0 0 
% Cytogenetic 
Response 
NR 44 36 52 NR NR NR NR - NR NR 
Complete 49 32 26 46 46 20 29 32 34 27 35 
Partial 11 7 7 6 15 12 10 16 13 20 18 
% Survival (at 12 
mo) 
96(15) 82(12) 50(12) 50(5) 87(24) 67(24) 42(12) 42(12) 98(12) 60(12) 50(10) 
AP: Accelerated Phase, CHR: Complete Hematological Response, CP: Chronic Phase, LyBP: Lymphoid Blast Phase, MyBP: Myeloid Blast Phase, MEL: 
No Evidence of Leukemia, NR: Not reported 
 
Investigational Agents for use after failures with two TKIs or in 
the presence of T315I mutations 
Ponatinib 
Ponatinib is a multikinase inhibitor that has shown the inhibitory 
activity of BCR-ABL wild-type, BCR-ABL-T315I, and all other tested 
variants. Initial dose escalation data showed efficacy at 30 mg daily 
with no dose-limiting toxicities. Preliminary data are available in 32 
patients with CML, Ph (+) ALL, and other hematologic malignancies. 
Twelve of the 32 patients exhibited T315I mutations. Of the twelve 
patients, 7 (58%) with CML-CP attained a CHR; 2 (17%) attained a 
CCyR (1 with CML-CP and 1 CML-AP), and 1 (8%) with CML-CP 
attained a PCyR. One patient with CML-CP with the nilotinib-resistant 
F359C mutation attained a CCyR and MMR on AP24534 [114]. 
Omacetaxine mepesuccinate 
The development of resistance to TKIs has led to the development of 
omacetaxine, a taxine with a mechanism of action independent of 
tyrosine kinase inhibition. Phase II/III studies in patients with CML 
status after failed therapy with multiple TKIs, and a significant 
proportion with baseline mutations, are ongoing. Preliminary data 
in patients without T315I mutations demonstrate 80% CHR rates, 
20% MCyR rates and 10% MMR rates in CML-CP patients; 75% 
hematologic response rates including return to chronic phase and 
CHR, and 5% CCyR rates in CML-AP; and 8% hematologic response 
rate including return to chronic phase and CHR in CMLBP [115]. In 
those with CML-CP with T315I mutations, results show achievement 
of an 85% CHR rate, 28% CyR rate, 15% MCyR rate, 15%MMRrate, 
and 57% reduction in the T315I clone. OS was not met in this group 
of patients. In CML-AP, 37.5% showed hematologic response with an 
OS of 18.8 mo. In CML-BP, the hematologic response was 
demonstrated in 30% with an OS of 1.8 mo [116].  
An update combining both of the above study populations was 
presented at the American Society of Hematology (ASH) annual 
meeting of 2010. Thirty-six of the 93 chronic-phase patients had 
been treated previously with three or more TKIs. Over a median 
follow-up period of 7.5 mo, 27 of 36 patients (75%) achieved or 
maintained a CHR and 7 (19%) achieved a major CyR (4 complete 
and 3 partial) with omacetaxine, with a median duration of at least 4 
mo. These findings support the further investigation of this agent in 
patients failing other TKI therapy [117]. Grade 3 to 4 hematologic AE 
included thrombocytopenia (65%), neutropenia (48%), anemia 
(40%), febrile neutropenia (12%), bone marrow failure (12%), 
pancytopenia (7%), and febrile bone marrow aplasia (6%). Grade 3 
to 4 nonhematologic AE included fatigue (6%). Grade 1-2 AE 
included diarrhea, fatigue, nausea, vomiting, fever, headache and 
asthenia [115-117]. 
Advanced drug therapy for CML 
Aurora kinase inhibitors 
The Aurora kinase family consists of serine-threonine kinases which are 
very important for different stages of the mitosis. Two family members 
of Aurora A and B found to be overexpressed in some neoplasias.  
Few of the following Aurora kinase inhibitors are in pre-clinical and 
clinical evaluation: PHA-739358 (danusertib), AT9283, MLN8237XL-
228, KW-2449 and MK-0457. Danusetib has been proven for safety and 
efficacy in patients having T315I mutation in phase I clinical study.  
AT9238 is a multi-kinase inhibitor which also inhibited cells with 
the T315I mutation. It has been observed that AT9238 is well-
tolerated during phase I clinical trial and having anti-leukemic 
activity [118-122]. 
Hsp90 
A molecular chaperone which interacts with various proteins like Raf, 
Akt, FLT-3 and Bcr-Abl, Hsp90 maintains these proteins in a stable and 
functional conformation. Geldanamycin and its derivative, 17-
allylamino-17-demethoxygeldanamycin (17-AAG) bind to the ATP-
binding pocket of Hsp90 and inhibit its chaperone activity which leads 
to down-regulation of Bcr-Abl and also induction of apoptosis in CML 
cell lines. It has also been found that Geldanamycin and 17-AAG 
inhibited the cell growth of some mutant lines (E255K and T315I). 
Hsp90 has its limits, and there are some cross-resistant types. It has 
been observed that combination therapy of imatinib and 17-AAG leads 
to synergistic inhibition of growth and induction of apoptosis in cross-
resistant cell lines but not in the imatinib-sensitive counterparts. 17-
AAG may also block the imatinib efflux [122, 123]. 
Arsenic trioxide (As2O3) 
Arsenic trioxide (As2O3) induces apoptosis in Bcr-Abl-positive cell 
lines and reduces proliferation of CML blasts without affecting the 
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CD34+progenitors. The combination of As2O3 with imatinib exerted 
additive to synergistic effect. This combination induced cell death in 
imatinib-resistant cell lines with overexpressed Bcr-Abl or bearing 
M351Tor Y253F mutations, but it does not affect the T315I mutants 
[123, 124]. 
Homoharringtonine (HHT) 
HHT is a by-product of a plant alkaloid which inhibits protein 
synthesis and induces apoptosis. The combination of HHT with 
imatinib is synergistic or additive on CML-derived cell lines. 
Omacetaxine and chemgenex are semisynthetic HHT derivatives that 
if combined with imatinib showed promising activities. Omacetaxine 
is now in phase II trials with TKIs-resistant patients with or without 
the T315I mutation [122, 123]. 
Histone deacetylases (HDAC) 
HDAC are the catalysts in deacetylation of lysine residues at the 
amino termini of nucleosomal core histones. Histone deacetylase 
inhibitors (HDI) such as suberoylanilide hydroxamic acid (SAHA, 
vorinostat) generates hyperacetylated histones which cause 
transcriptional upregulation of the cyclin-dependent kinase 
inhibitor, p21, cell-cycle arrest and apoptosis in tumor cells. It has 
also been found that SAHA induces expression of a key cell-cycle 
regulator p27, and its application is associated with downregulation 
of the p210 Bcr-Abl protein. The synergetic effect of inducing 
apoptosis in imatinib-resistant CML cell lines has been observed 
between SAHA and imatinib. The co-treatment with nilotinib and the 
HDI LBH589 (panobinostat) was very effective in inducing apoptosis 
in K-562 and LAMA-84 CML cell lines. LBH589 showed efficacy in 
imatinib-resistant cell lines bearing the T315I and E255K mutations, 
and this was associated with depletion of Bcr-Abl. A published study 
showed that when HDI valproate combined with imatinib, increase 
in antileukemic efficacy and sensitivity for imatinib-resistant CML 
cells occurs [123, 125]. 
Proteasomes 
Proteasomes cause degradation of different cellular proteins. 
Bortezomib, a proteasome inhibitor was shown to inhibit 
proliferation, to stop the cell cycle in the G2/M phase and to 
promote apoptosis in imatinib-sensitive and imatinib-resistant CML 
cell lines. Because of antagonistic drug-drug interactions, Co-
treatment of bortezomib and imatinib isn’t recommended. However, 
if a low dose bortezomib exposure of CML cell lines is followed by 
imatinib, there are some additive effects. Synergistic interactions 
between bortezomib and the HDI SAHA has also been reported and 
bortezomib with flavopiridol in in vitro as well [123]. 
Farnesyl transferase inhibitor (FTIs) 
Current FTIs as antileukemic agents like tipifarnib and lonafarnib are 
under investigation. Ras-MAPK signal pathway which is responsible 
for the formation of Bcr-Abl through protein-protein interactions 
are inhibited by FTIs and plays a central role in leukemogenic 
transformation. The combination imatinib and tipifarnib were well 
tolerated and active in patients with imatinib-resistant CML which 
T315I mutant. Lonafarnib is a selective inhibitor of primary 
progenitor cells derived from CML patients which reduced colony 
formation of progenitor cells and showed activity in imatinib-
resistant CML cell lines. 
Sorafenib (BAY 43-9006) 
Sorafenib (BAY 43-9006) is a multi-kinase inhibitor of the RAS/Raf 
pathway which is involved in leukemogenesis downstream from 
Bcr-Abl. Drug concentrations of 5-10 μM were found to induce 
apoptosis via the mitochondrial pathway in imatinib-resistant cell 
lines. The combination of sorafenib and vorinostat (HDAC inhibitor) 
triggers cell dysfunction through Mcl-1 downregulation and p21 
inhibition. Sorafenib is approved for the treatment of hepatocellular 
and renal cancers. Phase I and Phase II trials are also carried out in 
CML patients [122]. 
CI-1040 
CI-1040 was the first MEK inhibitor which entered a clinical trial in 
for the treatment of CML. CI-1040 in combinations with imatinib, 
dasatinib, HDAC inhibitors, arsenic trioxide and HSP 90 inhibitors 
has also been studied. CI-1040 with arsenic trioxide and HSP 90 
combinations were tested with a positive effect in patients with 
T315I mutation. Because of the challenging pharmacokinetic 
properties, clinical advancement is unlikely, but a derivate 
(PD0325901) is under development [122]. 
mTOR (mammalian target of rapamycin) 
The protein kinase, mTOR is a downstream mediator of the 
PI3K/Akt pathway which controls cell growth and survival. 
Rapamycin (sirolimus) is the prototype compound of this group, but 
clinical usefulness has been limited because it has poor aqueous 
solubility and chemical stability. However, in a small clinical trial, 
four out of six patients with imatinib-resistant disease responded to 
oral rapamycin. Rapamycin also significantly inhibited the cell 
growth in Ph+cell lines with or without the T315I mutation. The 
combination of imatinib and another mTOR inhibitor, everolimus, 
was associated with an increased expression of c-Abl and inhibition 
of Bcr-Abl. In the presence of inhibited Bcr-Abl, c-Abl enters the 
nucleus and modulates apoptosis. A Phase I trial with imatinib and 
everolimus has been completed while a study with temsirolimus is 
currently in accrual [122]. 
Investigational agents 
There are several new targeted tyrosine kinase inhibitors under 
development and targeted to the underlying causes of Imatinib 
resistance and disease progression (table). 
 
Drug target Drug target 
IMATINIB BCR-ABL, c-kit, and PDGFR * 
DASATINIB BVCR-ABL, SRC FAMILY 
KINASES, c-kit EPHRIN RECEPTOR 
KINASES and PDGFR 
NILOTINIB BCR-ABL, c-kit T, and PDGFR 
SKI-606 BCR-ABL and Src FAMILY KINASES 
VX-680 BCR-ABL, AURORA KINASES and FLT3 KINASE 
BIRB-796 BCR-ABL, P38 MAP+
ONO 12380 
KINASE 
BCR-ABL and LYN KINASE 
* PDGFR= Platelet Derived Growth Factor Receptor, +MAP= Mitogen-Activated Protein 
 
Most of these new molecules have shown promising in vitro activity 
against a subset of BCR-ABL mutants and also might suppress the 
proliferation of Imatinib-resistant cells in which the cause of the 
resistance is overexpression of BCR-ABL [126, 127]. 
Future concern 
Imatinib has transformed CML from an immediately life-threatening 
disease to one that is treatable with daily oral medication that makes 
it possible to improve both overall survival and maintain the quality 
of life. However, increasing the incidence of imatinib resistance and 
intolerance necessitates the development of alternative therapies. 
There is a substantial amount of data supporting the improvement 
in outcome in long-term follow-up of the second-generation TKIs, 
nilotinib and dasatinib. Improving outcome in the front-line setting 
should be the direction of further scientific research, including the 
implementation of second-generation TKIs as front-line therapy. 
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Despite extraordinary progress, a true cure for CML is not generally 
achieved by Abl kinase inhibitors. TKIs are potent inhibitors of 
BCRABL kinases (among others), resulting in rapid reduction of the 
majority of cells carrying the Ph chromosomal marker. However, 
suppression of ABL-driven hematopoiesis may be insufficient to 
eradicate quiescent stem cells. Studies assessing the combination of 
TKIs with promising agents are ongoing. These combinations 
include TKI and hedgehog inhibitors, omacetaxine, vaccines and 
hypomethylating agents. If successful, this strategy could lead to a 
safe and permanent discontinuation of therapy in patients with a 
good response. The impact of using more potent agents in the front-
line setting on the potential to discontinue TKI therapy remains to 
be determined. The future of CML therapy may include early use of 
these potent agents, perhaps in combination with new molecules, to 
help more patients achieve CMR, which could lead to therapy 
discontinuation and cure [128]. 
The use of vaccines directed against proteins associated with 
malignant cells might also be used to target T315I-carrying cells. In a 
small study in 16 patients with CP CML, and who were treated with 
imatinib or IFN-α, the addition of a vaccine targeting the BCR-ABL–
derived p210 fusion protein to therapy deepened cytogenetic 
responses in all patients [128, 129]. 
CONCLUSION 
The introduction of the BCR-ABL TKIs has revolutionized the 
management of Ph+CML patients. Patients diagnosed with CML 
today, as opposed to 10–20 y ago, are expected to have a 
substantially longer survival rate. However, further improvements 
in prognosis and complete disease eradication are goals that have 
yet to be reached in CML treatment. The use of first-generation BCR-
ABL TKI imatinib has yielded some degree of successes as a first-line 
therapy. However, there are some patients who are resistant or 
intolerant to imatinib therapy. The currently approved second-
generation TKIs, dasatinib and nilotinib, are effective in most 
patients who experience treatment failure with imatinib. However, 
these agents are not efficacious in a small group of resistant patients 
as a consequence of the interaction of multiple factors including 
T315I mutation. Indeed, advanced therapy and investigational new 
drugs in understanding chemotherapeutic failure have provided us 
with novel strategies to overcome CML disease. It seems pertinent to 
further explore and determine the resistance mechanisms and to 
ascertain the resistance profiles of these known BCR-ABL TKIs in 
order to provide the optimal treatment regimens. 
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